

**Ref: 74/SE/LC/2025-26**

**Date: February 03, 2026**

Scrip Code BSE: 544122  
NSE: ENTERO  
ISIN: INE010601016

To,

**Head, Listing Compliance Department  
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

Dear Sir/Madam,

**Sub: Intimation of Notice of Board Meeting.**

**Ref: Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('LODR')**

Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 12, 2026, *inter-alia*, to consider, approve and take on record the Unaudited Standalone and Consolidated Financial Results (along with Limited Review) of the Company for the quarter and nine months ended December 31, 2025.

As informed vide our letter dated December 23, 2025, the trading window for dealing in the securities of the Company is closed for all designated persons and their immediate relatives with effect from January 01, 2026 and will continue to remain closed till completion of 48 hours after declaration of aforesaid results unless communicated otherwise.

This is for your information and records.

Yours Faithfully

For **Entero Healthcare Solutions Limited**

Sanu Kapoor

**Vice President- General Counsel, Company Secretary  
& Compliance Officer**